Catalyst Dossier · compiled by CeliA 🧫

Camurus AB (CAMX.ST)

Pharmaceutical Preparations · market cap $3.1B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-15 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Camurus AB (CAMX.ST) is a Swedish specialty pharma company with 308 employees and a market cap of approximately $3.1B, focused on its proprietary FluidCrystal® injectable depot platform. The lead asset, CAM2029 (an octreotide subcutaneous depot), is in Phase 3 for both gastroenteropancreatic neuroendocrine tumors (GEP-NET) and acromegaly, with a high-importance Phase 3 readout for GEP-NET estimated around July 15, 2026. The pipeline also includes FluidCrystal® formulations of leuprolide acetate (Phase 2, prostate cancer) and octreotide (Phase 2, acromegaly).

The catalyst path

2026-07-15 (est.)Phase 3 · CAM2029imp 9/10

Pipeline

Asset	Phase	Indication
CAM2029	Phase 3	Gastro-enteropancreatic Neuroendocrine Tumor
octreotide FluidCrystal® injection depot	Phase 2	Acromegaly
leuprolide acetate FluidCrystal® injection depot	Phase 2	Prostate Cancer
CAM2029 (octreotide subcutaneous depot)	Phase 3	Acromegaly

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CAMX.ST (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.